# Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Sclerosis

> **NCT03113162** · PHASE1 · UNKNOWN · sponsor: **Makati Medical Center** · enrollment: 15 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** Autologous Hematopoietic Stem Cell
- **DRUG:** BEAM Regimen

## Key facts

- **NCT ID:** NCT03113162
- **Lead sponsor:** Makati Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-05-29
- **Primary completion:** 2020-05-29
- **Final completion:** 2022-05-29
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2017-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03113162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03113162, "Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Sclerosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03113162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*